CD8A and melanoma: A clinical trial (NCT03341143) demonstrated that FMT combined with anti-PD-1 therapy was well tolerated and provided clinical benefits in a subset of PD-1-refractory melanoma patients by modulating the gut microbiome, enhancing CD8+ T cell activation, and altering the tumor microenvironment to overcome therapy resistance [370].